Golexanolone affords sustained improvement of Parkinson's symptoms in rats by reducing microglia activation that restores the glutamate-GABA-dopamine pathway
{{output}}
Golexanolone improves motor and non-motor symptoms in the 6-OHDA rat model of Parkinson's disease (PD) and reduces neuroinflammation in the striatum, without inducing dyskinesias. To understand the underlying mechanisms, we hypothesized that activated microgl... ...
